Health
Immunotherapy after surgery offers recurrence-free survival advantage for patients with high-risk melanoma – News-Medical.Net
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either…
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients…
-
General20 hours agoFootballers and movie stars: PM’s Shanghai tourism push
-
Business19 hours agoNvidia reaches the $4 trillion mark. Can it hit $5 trillion in 2025?
-
Business19 hours agoThis artificial intelligence (AI) and “Magnificent Seven” stock will be the next company to surpass a $3 trillion market cap by the end of 2025
-
General17 hours ago‘Hidden and radical’ power of First Nations women unlocked in big hART’s Punkaliyarra project